The Role of SGLT2 Inhibitors in Cardiovascular Risk Reduction in Type 2 Diabetes.
1Dr Muhammad Rehan Khan, 2Dr Qurat-Ul-Ain Bukhari 3Marwa Khurram, 4Naznin tabbasum, 5Qaiser ikhlaq, 6Haroon raja
Submission: 06 December 2025 | Acceptance: 11 January 2026 | Publication: 19 February 2026
1Assistant professor cardiology Gomal Medical College DIK.
2Altamash Institute of Dental Medicine
3Liaqat Hospital, Karachi
4Service Hospital, Faisalabad
5UHS, Lahore
6Gangaram Hospital, Lahore
Abstract
Background:
Sodium-glucose co-transporter 2 inhibitors, usually developed for glycemic control in type 2 diabetes mellitus, have illustrated remarkable cardiovascular benefits in specific clinical trials. Their mechanism of action broadened beyond glucose lowering, purposing the pleiotropic effects that may give to reduced cardio-vascular risk.
Objective:
To find out the effectiveness of SGLT2 inhibitors in reduction of cardiovascular events between patients with T2DM and highlight patterns at different cardiovascular results.
Methods:
A Backdated group analysis of published randomized controlled trials and real-world studies was held. Patients with T2DM receiving SGLT2 inhibitors were linked for changes in cardio-vascular results including major adverse cardio-vascular events, heart failure hospitalization, and cardio-vascular mortality.
Results:
SGLT2 inhibitors remarkably reduced the risk of HFH less than 30% and CV mortality at 20% contrasting to placebo. The effect on MACE was more modest but statistically remarkable. Subgroup analyses highlight consistent benefits across age, sex, and comorbidities.
Conclusion:
SGLT2 inhibitors consult robust cardio-vascular protection in patients with T2DM, specifically in reducing HFH and CV death. These findings give strength to their broader use in T2DM management with cardio-vascular risk.
Keywords: Cardiovascular risk, heart strokes, mortality rate, inhibitors